HR 2343 · John W. Walsh Alpha-1 Home Infusion Act of 2025
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- Introduced
- Mar 25, 2025
- Latest action
- Mar 25, 2025
- Sponsor
- Rep. Maria Elvira Salazar [R-FL-27]
- Policy area
- Health
- Cosponsors
- 53
Summary
John W. Walsh Alpha-1 Home Infusion Act of 2025 This bill provides for Medicare coverage of treatment for alpha-1 antitrypsin (AAT) deficiency (a protein deficiency that raises the risk of lung and other diseases). Specifically, the bill provides for coverage of at-home augmentation therapy for beneficiaries with emphysema as a result of severe hereditary AAT deficiency. Treatment must be provided through qualified home infusion therapy suppliers; beneficiaries must be under the care of a physician, nurse practitioner, or physician assistant.
Recent actions
- Mar 25, 2025 Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- Mar 25, 2025 Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- Mar 25, 2025 Introduced in House
- Mar 25, 2025 Introduced in House
Votes
No recorded votes are available for this bill.